Skip to main content
Gubra A/S logo

Gubra A/S — Investor Relations & Filings

Ticker · GUBRA ISIN · DK0062266474 LEI · 254900T17RRFZONO6W53 CO Professional, scientific and technical activities
Open in API
Filings indexed 87 across all filing types
Latest filing 2025-08-20 Earnings Release
Country DK Denmark
Listing CO GUBRA

About Gubra A/S

https://www.gubra.dk/

Gubra A/S is a biotechnology company and preclinical Contract Research Organization (CRO) specializing in peptide-based drug discovery. The company operates a dual business model, providing preclinical research services to pharmaceutical and biotech clients while also developing its own proprietary pipeline of therapeutics. Gubra's primary focus is on metabolic diseases, such as obesity, diabetes, and MASH (metabolic dysfunction-associated steatohepatitis), as well as fibrotic diseases. Its research and development activities also extend into inflammatory conditions, CNS, respiratory, and women's health. The CRO services division supports clients in advancing their drug development programs through expertise in areas like in vivo pharmacology and peptide chemistry.

Recent filings

Filing Released Lang Actions
Record quarter for Gubra, but revised outlook for the CRO business
Earnings Release Classification · 95% confidence The document is a short announcement (under 5,000 characters) detailing a revision to the company's financial outlook for the CRO business and providing highlights of Q2 2025 performance. It explicitly states that the full half-year report will be published on a later date (21 August 2025). As it is an initial announcement of financial highlights and outlook revisions rather than the full report itself, it fits the definition of an Earnings Release (ER). Q2 2025
2025-08-20 English
Markus Rohrwild appointed new CEO of Gubra in a planned succession process
Board/Management Information Classification · 100% confidence The document is an official announcement regarding the appointment of a new CEO (Markus Rohrwild) and the departure of the current CEO (Henrik Blou) at Gubra. This falls directly under the category of board and management changes.
2025-08-12 English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Director's Dealing Classification · 100% confidence The document is a regulatory notification regarding transactions made by a person discharging managerial responsibilities (PDMR), specifically the CFO, Kristian Borbos. It details the granting of warrants as part of an incentive program. This falls under the category of 'Director's Dealing' (DIRS), which covers personal share transactions or financial instrument dealings by company directors and executives as required by the Market Abuse Regulation.
2025-07-10 Danish
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Director's Dealing Classification · 100% confidence The document is a notification of transactions made by a person discharging managerial responsibilities (PDMR), specifically the CEO, regarding the receipt of warrants. This falls under the category of 'Director's Dealing' (DIRS), which covers insider trades and transactions by company executives as required by the Market Abuse Regulation.
2025-07-10 Danish
Successful Transaction Closure of License Agreement
Regulatory Filings Classification · 95% confidence The document is a regulatory press release announcing the successful closure and effectiveness of a license agreement. It does not fit into specific categories like M&A (which usually refers to corporate takeovers/mergers) or other specialized financial reports. As it is a general regulatory announcement regarding a business development milestone, it falls under the fallback category for regulatory announcements.
2025-04-01 English
Gubra announces positive GUBamy Phase 1 interim MAD results
Regulatory Filings Classification · 95% confidence The document is a regulatory press release announcing positive interim Phase 1 clinical trial results for a drug candidate (GUBamy). It details clinical trial outcomes, safety data, and pharmacokinetic findings. As it is a corporate announcement of material clinical trial results rather than a full report or a simple publication notice, it falls under the category of general regulatory announcements/filings.
2025-04-01 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.